Condition: Staphylococcus Aureus · Sponsor: University Hospital Tuebingen
In this clinical trial we will test a new approach for decolonization of S. aureus. As innovative product HY-133 a recombinant chimeric bacteriophage endolysin will be sprayed in both nostrils of healthy subjects once or five times in one day. To avoid possible bias the subjects will be randomized 3:2 verum vs placebo, moreover the subject as well as the investigator will be blinded to the group assigned.
This description comes directly from the study's public registry record.
Sebastian Volc, PD · 07071 2926745 · studienzentrum.immundermatologie@med.uni-tuebingen.de
Always discuss trial participation with your own doctor first.
| Department of Dermatology, University Hospital Tuebingen | Tübingen, Germany | Recruiting |
| Department of Dermatology | Tübingen, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06290557